Research programme: endostatin-derived peptide therapeutics - iBio

Drug Profile

Research programme: endostatin-derived peptide therapeutics - iBio

Alternative Names: CFB 03; E4-Fc; IBIO-CFB 03; Peptide E4

Latest Information Update: 21 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Medical University of South Carolina
  • Developer iBio Inc; Medical University of South Carolina
  • Class Angiostatic proteins; Peptides; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Gelatinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Systemic scleroderma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis; Systemic scleroderma

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis; Systemic scleroderma

Most Recent Events

  • 21 Mar 2018 Preclinical development is ongoing in USA for Systemic scleroderma and Idiopathic pulmonary fibrosis
  • 05 Jul 2016 Research programme: endostatin-derived peptide therapeutics - iBio receives Orphan Drug status for Systemic scleroderma in USA
  • 29 Jun 2016 iBio has patent protection for endostatin-derived peptide therapeutics in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top